海藻酮治疗慢性乙型肝炎相关肝纤维化:一项2期随机对照试验
这项在中国8个中心开展的52周多中心、随机、双盲、安慰剂对照2期研究纳入168例慢性乙型肝炎伴肝纤维化患者,随机接受安慰剂或海藻酮180、270、360 mg/日口服,所有患者同时接受恩替卡韦0.5 mg/日。270 mg组纤维化改善率显著高于安慰剂组,总体安全性相似。
要点
- 270 mg组纤维化改善率54.8% vs 安慰剂组25.6%(P=.006)。
- 合并海藻酮组改善率46.4% vs 安慰剂组25.6%(P=.014)。
- 180 mg组和360 mg组改善率与安慰剂组无显著差异。
核心结论
- 海藻酮联合恩替卡韦在慢性乙型肝炎相关肝纤维化患者中显示出临床显著的组织学改善,270 mg剂量显示出最佳的纤维化逆转疗效。
- 需要进一步研究评估海藻酮逆转肝纤维化的长期有效性。
研究设计与样本
- 52周多中心、随机、双盲、安慰剂对照2期研究,在中国8个中心开展。
- 纳入168例经活检证实肝纤维化的慢性乙型肝炎患者,随机分为安慰剂组43例和海藻酮组125例(180 mg组42例、270 mg组42例、360 mg组41例)。
- 所有入组受试者同时接受恩替卡韦0.5 mg/日,第52周进行第二次肝活检。
- 主要终点定义为治疗第52周纤维化改善(Ishak评分至少降低1分)。
主要发现
- 纤维化改善终点达成:安慰剂组11例(25.6%),180 mg组17例(40.5%)(P=.12),270 mg组23例(54.8%)(P=.006),360 mg组18例(43.90%)(P=.08)。
- 合并海藻酮组改善率为58/125(46.4%)(P=.014)。
- 各组总体安全性和严重不良事件发生率相似。
- 研究时间为2015年6月25日至2019年9月5日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究评估海藻酮逆转肝纤维化的长期有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis B virus infection frequently leads to liver fibrosis and is the leading cause of hepatocellular carcinoma and cirrhosis in Asia Pacific. Pirfenidone is approved by the United States Food and Drug Administration for treatment of idiopathic pulmonary fibrosis, and hydronidone is a novel structural modification of pirfenidone with the aim of reducing hepatoxicity. We aimed to investigate the safety and efficacy of hydronidone in patients with chronic hepatitis B (CHB)-associated liver fibrosis. METHODS: This was a 52-week multicenter, randomized, double-blind, placebo-controlled, phase II study at 8 centers in China. Patients with CHB with biopsied documented liver fibrosis were eligible and were randomly assigned into receiving daily placebo or hydronidone orally (180 mg/day, 270 mg/day, or 360 mg/day). All enrolled subjects also received entecavir 0.5 mg/day. A second liver biopsy was performed at week 52. The primary endpoint was defined as fibrosis improvement (reduction of at least 1 Ishak score at week 52 of treatment). RESULTS: From June 25, 2015, to September 5, 2019, 168 patients with CHB and liver fibrosis met the inclusion/exclusion criteria and were subsequently randomized, 43 in the placebo group and 125 in the hydronidone groups (42 in the 180-mg group, 42 in the 270-mg group, and 41 in the 360-mg group). The fibrosis improvement endpoint was achieved by 11 patients (25.6%) in the placebo group and 17 patients (40.5%) in the 180-mg group (P = .12), 23 patients (54.8%) in the 270-mg group (P = .006), and 18 patients (43.90%) in the 360-mg group (P = .08). The improvement rate was 58 of 125 (46.4%) in the combined hydronidone group (P = .014). The overall safety profile and incidence of serious adverse events were similar among the groups. CONCLUSIONS: Hydronidone plus entecavir showed clinically significant histological improvement of liver fibrosis in patients with CHB, and the dose of 270 mg showed the best efficacy of fibrosis regression. Further studies are required to assess the long-term effectiveness of hydronidone in regression of hepatic fibrosis. CLINICALTRIALS: gov number, NCT02499562.
引用
- Cai X, Liu X, Xie W, et al. Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2022. PMID: 35842120. doi:10.1016/j.cgh.2022.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。